Fundraising Fox
/Companies
Sign in

GlycoEra

Newton, US · 9 known investors

Find your way into GlycoEra

Sign up to see every warm intro you have to GlycoEra

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the GlycoEra team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.

BiotechHealthtech

Founders & leadership

GVGanesh V. Kaundinya
Ganesh V. KaundinyaPresident & CEO

Investors · 9

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

LifeArc Ventureslisted by LifeArc VenturesLondon
Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Sixty Degree Capitallisted by Sixty Degree CapitalNorth York

How we know: Sixty Degree Capital's portfolio page · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Agent CapitalreportedWaltham

How we know: press coverage · the VCSheet dataset · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: a partner's Signal profile · funding news · Not right? Tell us

Also in the syndicate · 1

Novo

Funding

SEC filings, press & company announcements

$130M disclosed across 1 of 3 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through GlycoEra went on to found or lead other companies.

Kush M ParmarBoard MemberFounded Homology MedicinesVeronica Gambillara FonckCEO-and Co-FounderFounded LimmaTech Biologics

Related companies · 6

AbCelleraAbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
NucleraNuclera provides multiplex protein screening technology for life science researchers, enabling faster access to and testing of proteins for drug discovery and development. The company serves protein scientists and research teams accelerating breakthroughs in structural biology and functional studies.
DecipheraDeciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.
Chimera BioengineeringChimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy. The company focuses on treating solid tumors and other currently incurable cancers through localized, controlled immune cell activation.
Galera TherapeuticsGalera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.
Kymera TherapeuticsKymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.

Companies working in the same space as GlycoEra.

Frequently asked questions

What does GlycoEra do?
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs. The company operates in the biotech and drug development space.
Who are GlycoEra's investors?
GlycoEra's investors include 5AM Ventures, Catalio Capital Management, LP, LifeArc Ventures, Roche Venture Fund, Sixty Degree Capital, Sofinnova Partners, Agent Capital, Novo Holdings.
How much funding has GlycoEra raised?
GlycoEra has disclosed $130M raised across 1 of its 3 known rounds.
Where is GlycoEra headquartered?
GlycoEra is headquartered in Newton, US.